Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

Journal Browser

COVID-19 in the ICU: One Year Later: Recent Advances in Critical Care

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Anesthesiology".

Deadline for manuscript submissions: closed (15 May 2022) | Viewed by 7364

Share This Special Issue

Special Issue Editor

Dr. Florence Boissier

E-Mail Website
Guest Editor

1. Medical ICU, University Hospital of Poitiers, Poitiers, France;
2. INSERM CIC 1402 (ALIVE Group), Poitiers University, Poitiers, France
Interests: intensive care; echocardiography; hemodynamics; ARDS; septic shock; respiratory weaning; end of life

Special Issue Information

Dear Colleagues,

One year later, the COVID-19 pandemy is still ongoing and the capacity of intensive care departments is one of the determinants of political decisions. However, many advances have been made in the care of ICU COVID-19 patients in one year, regarding specific drugs, the use of respiratory devices and respiratory settings, and the diagnosis and care of associated critical complications (e.g., neurological, cardiac, thromboembolic). Local and territorial organization, the protection of caregivers, the impact of sanitary protocols on the next-of-kin, and the impact of COVID-19 care on the other usual critical care pathologies are also crucial questions. The typology and prognosis of patients have also changed in the course of one year.

This Special Issue aims to describe these physiopathological, diagnostic, and therapeutic advances in the specific population of critically ill patients.

We are looking forward to receiving your original articles, reviews, and short communications about this hot topic!

Dr. Florence Boissier
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Intensive care
COVID-19
ARDS
Acute respiratory failure
Critically ill patients

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

10 pages, 576 KiB

Open AccessArticle

Potential of Multiplex Polymerase Chain Reaction Performed on Protected Telescope Catheter Samples for Early Adaptation of Antimicrobial Therapy in ARDS Patients

by Keyvan Razazi, Flora Delamaire, Vincent Fihman, Mohamed Ahmed Boujelben, Nicolas Mongardon, Ségolène Gendreau, Quentin de Roux, Nicolas de Prost, Guillaume Carteaux, Paul-Louis Woerther and Armand Mekontso Dessap

J. Clin. Med. 2022, 11(15), 4366; https://doi.org/10.3390/jcm11154366 - 27 Jul 2022

Cited by 5 | Viewed by 1407

Abstract

Background: Diagnosis of co/superinfection in patients with Acute Respiratory Distress Syndrome (ARDS) is challenging. The FilmArray Pneumonia plus Panel (bioMérieux, France), a new rapid multiplex Polymerase Chain Reaction (mPCR), has never been assessed on a blinded protected telescope catheter (PTC) samples, a very common diagnostic tool in patients under mechanical ventilation. We evaluated the performance of mPCR on PTC samples compared with conventional culture and its impact on antibiotic stewardship. Methods: Observational study in two intensive care units, conducted between March and July 2020, during the first wave of the COVID-19 pandemic in France. Results: We performed 125 mPCR on blinded PTC samples of 95 ARDS patients, including 73 (77%) SARS-CoV-2 cases and 28 (29%) requiring extracorporeal membrane oxygenation. Respiratory samples were drawn from mechanically ventilated patients either just after intubation (n = 48; 38%) or later for suspected ventilator-associated pneumonia (VAP) (n = 77; 62%). The sensitivity, specificity, positive, and negative predictive values of mPCR were 93% (95% CI 84–100), 99% (95% CI 99–100), 68% (95% CI 54–83), and 100% (95% CI 100–100), respectively. The overall coefficient of agreement between mPCR and standard culture was 0.80 (95% CI 0.68–0.89). Intensivists changed empirical antimicrobial therapy in only 14% (18/125) of cases. No new antibiotic was initiated in more than half of the CAP/HAP pneumonia-suspected cases (n = 29; 60%) and in more than one-third of those suspected to have VAP without affecting or delaying their antimicrobial therapy. Conclusions: Rapid mPCR was feasible on blinded PTC with good sensitivity and specificity. New antibiotics were not initiated in more than half of patients and more than one-third of VAP-suspected cases. Further studies are needed to assess mPCR potential in improving antibiotic stewardship. Full article

(This article belongs to the Special Issue COVID-19 in the ICU: One Year Later: Recent Advances in Critical Care)

► Show Figures

Figure 1

12 pages, 866 KiB

Open AccessArticle

Dynamic of Serum TWEAK Levels in Critically Ill COVID-19 Male Patients

by Marijana Mikacic, Marko Kumric, Martina Baricevic, Daria Tokic, Sanda Stojanovic Stipic, Ivan Cvitkovic, Daniela Supe Domic, Tina Ticinovic Kurir and Josko Bozic

J. Clin. Med. 2022, 11(13), 3699; https://doi.org/10.3390/jcm11133699 - 27 Jun 2022

Cited by 5 | Viewed by 2014

Abstract

Although the number of cases and mortality of COVID-19 are seemingly declining, clinicians endeavor to establish indicators and predictors of such responses in order to optimize treatment regimens for future outbreaks of SARS-CoV-2 or similar viruses. Considering the importance of aberrant immune response in severe COVID-19, in the present study, we aimed to explore the dynamic of serum TNF-like weak inducer of apoptosis (TWEAK) levels in critically-ill COVID-19 patients and establish whether these levels may predict in-hospital mortality and if TWEAK is associated with impairment of testosterone levels observed in this population. The present single-center cohort study involved 66 men between the ages of 18 and 65 who were suffering from a severe type of COVID-19. Serum TWEAK was rising during the first week after admission to intensive care unit (ICU), whereas decline to baseline values was observed in the second week post-ICU admission (p = 0.032) but not in patients who died in hospital. Receiver-operator characteristics analysis demonstrated that serum TWEAK at admission to ICU is a significant predictor of in-hospital mortality (AUC = 0.689, p = 0.019). Finally, a negative correlation was found between serum TWEAK at admission and testosterone levels (r = −0.310, p = 0.036). In summary, serum TWEAK predicts in-hospital mortality in severe COVID-19. In addition, inflammatory pathways including TWEAK seem to be implicated in pathophysiology of reproductive hormone axis disturbance in severe form of COVID-19. Full article

(This article belongs to the Special Issue COVID-19 in the ICU: One Year Later: Recent Advances in Critical Care)

► Show Figures

Figure 1

12 pages, 671 KiB

Open AccessArticle

Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation—A Retrospective Cohort Study

by Kevin Roedl, Ahmel Kahn, Dominik Jarczak, Marlene Fischer, Olaf Boenisch, Geraldine de Heer, Christoph Burdelski, Daniel Frings, Barbara Sensen, Axel Nierhaus, Stephan Braune, Yalin Yildirim, Alexander Bernhardt, Hermann Reichenspurner, Stefan Kluge and Dominic Wichmann

J. Clin. Med. 2021, 10(22), 5440; https://doi.org/10.3390/jcm10225440 - 21 Nov 2021

Cited by 12 | Viewed by 3078

Abstract

Extracorporeal membrane oxygenation (ECMO) represents a viable therapy option for patients with refractory acute respiratory distress syndrome (ARDS). Currently, veno-venous (vv) ECMO is frequently used in patients suffering from coronavirus disease 2019 (COVID-19). VV-ECMO was also frequently utilised during the influenza pandemic and experience with this complex and invasive treatment has increased worldwide since. However, data on comparison of clinical characteristics and outcome of patients with COVID-19 and influenza-related severe ARDS treated with vv-ECMO are scarce. This is a retrospective analysis of all consecutive patients treated with vv/(veno-arterial)va-ECMO between January 2009 and January 2021 at the University Medical Centre Hamburg-Eppendorf in Germany. All patients with confirmed COVID-19 or influenza were included. Patient characteristics, parameters related to ICU and vv/va-ECMO as well as clinical outcomes were compared. Mortality was assessed up to 90 days after vv/va-ECMO initiation. Overall, 113 patients were included, 52 (46%) with COVID-19 and 61 (54%) with influenza-related ARDS. Median age of patients with COVID-19 and influenza was 58 (IQR 53–64) and 52 (39–58) years (p < 0.001), 35% and 31% (p = 0.695) were female, respectively. Charlson Comorbidity Index was 3 (1–5) and 2 (0–5) points in the two groups (p = 0.309). Median SAPS II score pre-ECMO was 27 (24–36) vs. 32 (28–41) points (p = 0.009), and SOFA score was 13 (11–14) vs. 12 (8–15) points (p = 0.853), respectively. Median P/F ratio pre-ECMO was 64 (46–78) and 73 (56–104) (p = 0.089); pH was 7.20 (7.16–7.29) and 7.26 (7.18–7.33) (p = 0.166). Median days on vv/va-ECMO were 17 (7–27) and 11 (7–20) (p = 0.295), respectively. Seventy-one percent and sixty-nine percent had renal replacement therapy (p = 0.790). Ninety-four percent of patients with COVID-19 and seventy-seven percent with influenza experienced vv/va-ECMO-associated bleeding events (p = 0.004). Thirty-four percent and fifty-five percent were successfully weaned from ECMO (p = 0.025). Ninety-day mortality was 65% and 57% in patients with COVID-19 and influenza, respectively (p = 0.156). Median length of ICU stay was 24 (13–44) and 28 (16–14) days (p = 0.470), respectively. Despite similar disease severity, the use of vv/va-ECMO in ARDS related to COVID-19 and influenza resulted in similar outcomes at 90 days. A significant higher rate of bleeding complications and thrombosis was observed in patients with COVID-19. Full article

(This article belongs to the Special Issue COVID-19 in the ICU: One Year Later: Recent Advances in Critical Care)

► Show Figures

Journal Menu

Journal Browser

COVID-19 in the ICU: One Year Later: Recent Advances in Critical Care

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (3 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI